BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.
Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.
BioArctic (NASDAQ STOCKHOLM: BIOA B) ha annunciato che la CEO Gunilla Osswald 猫 stata nominata Alumna dell'Anno 2025 dall'Universit脿 di Uppsala. Il riconoscimento sottolinea la sua leadership esemplare e il contributo all'innovazione scientifica, in particolare per lo sviluppo di lecanemab per il morbo di Alzheimer.
All'inizio di marzo 2025, Osswald e i fondatori di BioArctic hanno ricevuto anche il Premio all'Innovazione e all'Imprenditorialit脿 dell'universit脿. L'ateneo ha elogiato il suo stile di guida visionario e inclusivo, evidenziando la capacit脿 di promuovere la collaborazione e di essere un modello per le donne nelle scienze e nella tecnologia.
BioArctic (NASDAQ STOCKHOLM: BIOA B) anunci贸 que la directora ejecutiva Gunilla Osswald ha sido nombrada Alumna del A帽o 2025 por la Universidad de Uppsala. El reconocimiento resalta su liderazgo ejemplar y sus aportes a la innovaci贸n cient铆fica, especialmente en el desarrollo de lecanemab para la enfermedad de Alzheimer.
A principios de marzo de 2025, Osswald y los fundadores de BioArctic tambi茅n recibieron el Premio a la Innovaci贸n y el Emprendimiento de la universidad. La instituci贸n elogi贸 su estilo de liderazgo visionario e inclusivo, destacando su capacidad para fomentar la colaboraci贸n y servir de referente para las mujeres en la ciencia y la tecnolog铆a.
BioArctic (NASDAQ STOCKHOLM: BIOA B)電� CEO Gunilla Osswald臧� 鞗侅偞霛� 雽�頃欖潣 2025雲� 霃欕靸�(Alumnus of the Year)鞚� 靾橃儊頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 響滌敖鞚� 鞎岇笭頃橃澊毹鸽硲 旃橂鞝� 霠堨勾雱る(lecanemab) 臧滊皽鞚� 韽暔頃� 瓿柬暀鞝� 順侅嫚鞐� 雽�頃� 攴鸽厐鞚� 氇矓鞝侅澑 毽崝鞁臣 旮办棳毳� 臧曥“頃╇媹雼�.
2025雲� 3鞗� 齑堨棎電� Osswald鞕� BioArctic鞚� 彀届梾鞛愲摛鞚� 雽�頃欖潣 順侅嫚路旮办梾臧�靸侂弰 靾橃儊頄堨姷雼堧嫟. 雽�頃� 旄§潃 攴鸽厐鞚� 牍勳爠 鞛堦碃 韽毄鞝侅澑 毽崝鞁� 鞀ろ儉鞚检潉 旃艾頃橂┌, 順戩梾鞚� 齑夓頃橁碃 瓿柬暀路旮办垹 攵勳暭 鞐劚霌れ潣 搿る雿胳澊 霅橁碃 鞛堧嫟瓿� 韽夑皜頄堨姷雼堧嫟.
BioArctic (NASDAQ STOCKHOLM: BIOA B) a annonc茅 que sa PDG Gunilla Osswald a 茅t茅 d茅sign茅e Dipl么m茅e de l'ann茅e 2025 par l'Universit茅 d'Uppsala. Cette distinction met en valeur son leadership exemplaire et ses contributions 脿 l'innovation scientifique, notamment dans le d茅veloppement du lecanemab pour la maladie d'Alzheimer.
D茅but mars 2025, Osswald et les fondateurs de BioArctic ont 茅galement re莽u le prix de l'innovation et de l'entrepreneuriat de l'universit茅. L'茅tablissement a salu茅 son style de direction visionnaire et inclusif, soulignant sa capacit茅 脿 favoriser la collaboration et 脿 servir de mod猫le pour les femmes en sciences et technologies.
BioArctic (NASDAQ STOCKHOLM: BIOA B) gab bekannt, dass CEO Gunilla Osswald zur Alumna des Jahres 2025 der Universit盲t Uppsala ernannt wurde. Die Auszeichnung w眉rdigt ihre vorbildliche F眉hrung und ihren Beitrag zur wissenschaftlichen Innovation, insbesondere bei der Entwicklung von Lecanemab f眉r die Alzheimer-Krankheit.
Anfang M盲rz 2025 erhielten Osswald und die Gr眉nder von BioArctic zudem den Innovations- und Unternehmerpreis der Universit盲t. Die Hochschule lobte ihren vision盲ren und inklusiven F眉hrungsstil und hob ihre F盲higkeit hervor, Zusammenarbeit zu f枚rdern und als Vorbild f眉r Frauen in Wissenschaft und Technik zu dienen.
- None.
- None.
The motivation reads: As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration-both within the organization and in dialogue with external partners. Gunilla Osswald is an inspiring role model for students and researchers, especially women in science and technology. Her work demonstrates that it is possible to unite scientific integrity with leadership, entrepreneurship, and global impact.
Gunilla Osswald trained as a pharmacist and earned a PhD at Uppsala University. Since 2014, she has served as CEO of BioArctic. Earlier this year, on March 12, 2025, Gunilla Osswald, together with BioArctic's two founders, Lars Lannfelt and P盲r Gellerfors, was awarded Uppsala University's Innovation and Entrepreneurship Prize for successfully addressing a growing global health problem through their work in developing the drug lecanemab, which slows the progression of Alzheimer's disease.
"Universities play a vital role in development and innovation. I am deeply honored by this award. Uppsala University has had a profound influence on who I have become as well as on the successes our company has achieved. My driving force has always been to help patients, and through my studies at the Faculty of Pharmacy, I laid the foundation for this important work," says Gunilla Osswald, CEO of BioArctic and Uppsala University's Alumnus of the Year 2025.
The information was released for public disclosure, through the agency of the contact person below, on September 9, 2025, at 09:00 CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR听
贰-尘补颈濒:听[email protected]
Phone: +46 70 410 71 80鈥�
Images of Gunilla Osswald can be found on the company website:
Motivation
As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration-both within the organization and in dialogue with external partners. Gunilla Osswald is an inspiring role model for students and researchers, especially women in science and technology. Her work demonstrates that it is possible to unite scientific integrity with leadership, entrepreneurship, and global impact.
About the Uppsala University Alumnus of the Year Award
Each year, Uppsala University presents the Alumnus of the Year award to someone who has made outstanding contributions in their career or has otherwise distinguished themselves through work that the university deems worthy of recognition. 听
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi庐 (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter鈩� technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap/articles/market-capitalization-explained" title="Read: What Is Market Capitalization and How It Is Calculated" class="article-link" rel="noopener">Large Cap. For further information, please visit .
This information was brought to you by Cision
The following files are available for download:
| Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 |
| Gunilla Osswald |
听
View original content:
SOURCE BioArctic
FAQ
Who is Gunilla Osswald and what award did she receive in 2025?
What achievements led to Gunilla Osswald's recognition at Uppsala University?
What other award did BioArctic's CEO receive from Uppsala University in 2025?
What is Gunilla Osswald's educational background?
